Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

New England Journal of Medicine

Volumn 345, Issue 10, 2001, Pages 747-755

  Kazatchkine, Michel D ^a,b,c   Kaveri, Srini V ^a,b  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHILL; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG SAFETY; EFFECTOR CELL; FATIGUE; HEADACHE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATORY DISEASE; MYALGIA; NAUSEA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; T-LYMPHOCYTES;

EID: 0035818044     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra993360     Document Type: Review

References (92)

1. Immunologically active proteins in intravenous immunoglobulin
2. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations
3. Natural autoantibodies
4. Positive selection of natural autoreactive B cells
5. Analysis of the natural human IgG antibody repertoire: Life-long stability of reactivities towards self antigens contrasts with age-dependent diversification of reactivities against bacterial antigens
6. Natural autoantibodies: From "horror autotoxicus" to "gnothi seauton"
7. A view of the human idiotypic repertoire: Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG
8. Self-reactive anti-bodies (natural autoantibodies) in healthy individuals
9. A monoclonal autoantibody that promotes central nervous system remyelination in a model of multiple sclerosis is a natural autoantibody encoded by germline immunoglobulin genes
10. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis
11. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig
12. Anti-idiotypes against autoantibodies in normal immunoglobulins: Evidence for network regulation of human autoimmune responses
13. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain
14. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)
15. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIg)
16. High-avidity autoantibodies to cytokines
17. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations
18. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use
19. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway
20. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
21. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg)
22. Natural mouse and human antibodies bind to a peptide derived from a germline VH chain: Evidence for evolutionary conserved self-binding locus
23. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies
24. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig)
25. Apoptosis by death factor
26. Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G
27. The biochemistry of apoptosis
28. Therapeutic immunomodulation with normal polyspecific immunoglobulin G (intravenous immunoglobulin, IVIg)
29. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders
30. Intravenous immunoglobulin treatment of neurological autoimmune diseases
31. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
32. Safety of intravenous immunoglobulin preparations: A prospective multicenter study to exclude the risk of non-A, non-B hepatitis
33. Intravenous IgG in Guillain-Barre syndrome
34. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome
35. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, cross-over study
36. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis
37. Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies
38. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis
39. Dermatomyositis: Remission induced with combined oral cyclosporine and high-dose intravenous immune globulin
40. The treatment of Kawasaki syndrome with intravenous gamma globulin
41. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation
42. Pooled intravenous immunoglobulin in the management of systemic vasculitis
43. New treatment strategies for systemic vasculitis: The role of intravenous immune globulin therapy
44. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy
45. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting sclerosis
46. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis
47. Intravenous immunoglobulin treatment in multiple sclerosis: Effect on relapses
48. Adverse effects of intravenous immunoglobulin therapy
49. Side effects of high-dose intravenous immunoglobulins
50. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies
51. Adverse effects of intravenous immunoglobulin
52. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy
53. IgA anaphylactic transfusion reactions
54. Insuffisance rénale aiguë secondaire à l'administration d'immunoglobulines intraveineuses: Quatre observations et revue de la littérature
55. Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissible agents
56. Fc receptor biology
57. Effect of intravenous immunoglobulin in immune thrombocytopenia: Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells?
58. Modulation of mononuclear phagocyte function by intravenous gamma-globulin
59. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin
60. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody
61. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura
62. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor
63. Intravenous immune globulin therapy for neurologic diseases
64. Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis
65. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
66. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes
67. Glomerulonephritis associated with complete deficiency of the fourth component of complement: Response to intravenous immunoglobulin
68. Pooled human IgG modulates cytokine production in lymphocytes and monocytes
69. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG
70. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)
71. IL-1 receptor antagonist and IL-1β production in human monocytes are regulated differently
72. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease
73. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo
74. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome
75. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: A possible mechanism of action in vascular diseases
76. In vitro correlates of the L. casei animal model of Kawasaki disease
77. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens
78. Intravenous immunoglobulin (IVIg) modulates the expansion of V beta 3+ and V beta 17+ T cells induced by staphylococcal enterotoxin B superantigen in vitro
79. Kawasaki syndrome: Immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin
80. Anticytotoxin-neutralizing antibodies in immune globulin preparations: Potential use in hemolytic-uremic syndrome
81. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin
82. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin
83. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins
84. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis
85. IgG autoantibody activity in normal mouse serum is controlled by IgM
86. Expression and control of the natural autoreactive IgG repertoire in normal human serum
87. Observations on the mode of action of normal immunoglobulin at high doses
88. Reduction in serum levels of antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC)
89. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice
90. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis
91. Suppression of experimental autoimmune encephalomyelitis by intravenous immunoglobulin